| 產(chǎn)品名稱 |
Human herpesvirus 5 |
| 商品貨號(hào) |
B163020 |
| Classification |
Herpesviridae, Cytomegalovirus |
| Deposited As |
Cytomegalovirus |
| Agent |
Human herpesvirus 5 |
| Strain |
Towne |
| Common Name |
Human cytomegalovirus |
| Applications |
Quality control Sexually Transmitted Disease Research |
| Biosafety Level |
2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format |
frozen 1 mL per vial |
| Shipping Information |
Infected viable cells + 7% DMSO |
| Storage Conditions |
Liquid nitrogen vapor phase |
| Comments |
Add contents of thawed ampule to a 80-85% monolayer of HDF cells. If foci of CPE fail to spread by day 11 PI, split infected cells 1:2 and observe for CPE as monolayer reforms. Attenuated for man, broad antigenicity. Stable for 6 months at -60°C in form of glycerinated cells. Virus primarily cell associated. A long (10-11 day) incubation is required for initial passage of frozen stocks. |
| Effect on Host |
CPE, cells round, become refractile, eventually slough off the flask |
| Recommended Host |
MRC-5 (ATCC® CCL-171™) |
| Growth Conditions |
Temperature: 37°C
Recommendations For Infection: Trypsinize a 2-4 day old cell culture and seed at a density of 105 cells per cm2 (2.5X106 cells/T25 flask; 7.5X 105 cells per T75 flask) using the virus growth medium (VGM). To the freshly trypsinized cells inoculate using a MOI of 0.1. Immediately add additional VGM depending upon the size of the flask used (recommended medium volume for T25 is 5 to 7 mL and for T75 15 to 22.5 mL). Incubate for 24 hours at 37°C in a 5% CO2 atmosphere. Aspirate media and add fresh virus/cell growth medium to remove any traces of DMSO. Continue incubation.
Incubation: 2-7 days in a 5% CO2 air atmosphere in a stationary position until CPE is seen
|
| Name of Depositor |
SA Plotkin |
| Special Collection |
NCRR Contract |
| Source |
Urine, man with congenital cytomegalic inclusion disease |
| References |
Plotkin SA, et al. Candidate cytomegalovirus strain for human vaccination. Infect. Immun. 12: 521-527, 1975. PubMed: 170203
Quality Control of Microbiological Transport Systems; Approved Standard. Wayne, PA. Clinical and Laboratory Standards Institute; CLSI M40-A.
|
